Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.
8 affiliations
- 1Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation, Rio de Janeiro, BRA.
- 2Molecular Medicine, Federal University of Minas Gerais, Belo Horizonte, BRA.
- 3Pediatric Infectious Diseases, Ministry of Health, Brasília, BRA.
- 4Vigilance of COVID-19, Influenza and Other Respiratory Viruses, Ministry of Health, Brasília, BRA.
- 5Scientific Computing, Oswaldo Cruz Foundation, Rio de Janeiro, BRA.
- 6Vigilance in Health and Environment, Department of Transmissible Diseases, Ministry of Health, Brazilia, BRA.
- 7Nursing, Belo Horizonte Municipal Health Department, Belo Horizonte, BRA.
- 8Health, Belo Horizonte Municipal Government, Belo Horizonte, BRA.
Abstract
The rise in post-infectious syndromes following COVID-19, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Postural Orthostatic Tachycardia Syndrome (POTS), has become increasingly common in clinical practice, representing an emerging clinical challenge. This case highlights a possible clinical scenario involving the interaction between sequential viral infections - such as the Epstein-Barr virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - in triggering overlapping chronic conditions. This report presents the case of a patient who developed ME/CFS and POTS following SARS-CoV-2 infection, with a prior history of EBV mononucleosis, and discusses the diagnostic, therapeutic, and pathophysiological implications. A 48-year-old woman with a history of mononucleosis in childhood developed persistent and disabling symptoms after COVID-19 in January 2022. She presented with extreme fatigue, orthostatic intolerance, paresthesia, cognitive dysfunction, and multisystem symptoms. After extensive investigation, she was diagnosed with ME/CFS (early 2023) and POTS (later that year). Mast Cell Activation Syndrome (MCAS) was considered as a hypothesis during follow-up, but objective testing was not confirmatory. Management included pharmacological therapy (including low-dose naltrexone, duloxetine, and palmitoylethanolamide (PEA)), activity adjustments (pacing), and a multidisciplinary approach, with partial and fluctuating responses. This case illustrates how viral infections such as EBV and SARS-CoV-2 may act as sequential triggers in an individual clinical trajectory compatible with the development of ME/CFS and POTS. The symptomatic overlap, the lack of readily available objective biomarkers in this patient, and the need for a predominantly clinical and functional diagnostic approach in her evaluation highlight the complexity of these conditions. This experience also underscores the importance of continued efforts in research, clinical training, and integrated care models to improve the management of patients presenting with post-COVID conditions (PCC).
Related
- Effectiveness of Individualized Physical Exercise in COVID-19-Induced Postural Orthostatic Tachycardia Syndrome.
- Post-translational modifications in the insoluble fraction of platelet-poor plasma distinguish pre-COVID-19 Postural Orthostatic Tachycardia Syndrome, Long COVID, and Long COVID-POTS: a preliminary study.
- Middle East Respiratory Syndrome Coronavirus in Camels, Kazakhstan, 2025
- Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands
- Global Genomic Surveillance of Middle East Respiratory Syndrome Coronavirus
BibTeX
@article{magalhaes2026overlapping,
title = {{Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.}},
author = {Virgínia R Mayrink Magalhães and Laura A Ribeiro Oliveira and Adelina J Lourenço and Isabela Ribeiro Camargos and Lucas G Da Silva and Priscilla S Filgueiras and Ana E De Souza Lima and Sarah V Marques Contin and Marcela Costa and Plinio Istilli and Marcelo Ferreira da Costa Gomes and Camila B Pedretti and Paulo Roberto Lopes Correa and Rafaella F Grenfell},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116844},
url = {https://europepmc.org/article/MED/42927133},
note = {CC BY},
}
RIS
TY - JOUR
TI - Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.
AU - Virgínia R Mayrink Magalhães
AU - Laura A Ribeiro Oliveira
AU - Adelina J Lourenço
AU - Isabela Ribeiro Camargos
AU - Lucas G Da Silva
AU - Priscilla S Filgueiras
AU - Ana E De Souza Lima
AU - Sarah V Marques Contin
AU - Marcela Costa
AU - Plinio Istilli
AU - Marcelo Ferreira da Costa Gomes
AU - Camila B Pedretti
AU - Paulo Roberto Lopes Correa
AU - Rafaella F Grenfell
PY - 2026
DA - 2026/09/24
JO - Cureus
DO - 10.7759/cureus.116844
UR - https://europepmc.org/article/MED/42927133
AB - The rise in post-infectious syndromes following COVID-19, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Postural Orthostatic Tachycardia Syndrome (POTS), has become increasingly common in clinical practice, representing an emerging clinical challenge. This case highlights a possible clinical scenario involving the interaction between sequential viral infections - such as the Epstein-Barr virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - in triggering overlapping chronic conditions. This report presents the case of a patient who developed ME/CFS and POTS following SARS-CoV-2 infection, with a prior history of EBV mononucleosis, and discusses the diagnostic, therapeutic, and pathophysiological implications. A 48-year-old woman with a history of mononucleosis in childhood developed persistent and disabling symptoms after COVID-19 in January 2022. She presented with extreme fatigue, orthostatic intolerance, paresthesia, cognitive dysfunction, and multisystem symptoms. After extensive investigation, she was diagnosed with ME/CFS (early 2023) and POTS (later that year). Mast Cell Activation Syndrome (MCAS) was considered as a hypothesis during follow-up, but objective testing was not confirmatory. Management included pharmacological therapy (including low-dose naltrexone, duloxetine, and palmitoylethanolamide (PEA)), activity adjustments (pacing), and a multidisciplinary approach, with partial and fluctuating responses. This case illustrates how viral infections such as EBV and SARS-CoV-2 may act as sequential triggers in an individual clinical trajectory compatible with the development of ME/CFS and POTS. The symptomatic overlap, the lack of readily available objective biomarkers in this patient, and the need for a predominantly clinical and functional diagnostic approach in her evaluation highlight the complexity of these conditions. This experience also underscores the importance of continued efforts in research, clinical training, and integrated care models to improve the management of patients presenting with post-COVID conditions (PCC).
SN - 2168-8184
ER -